Table 3.
Antimicrobial susceptibility and ESBL-producing of Salmonella isolates from clinical specimens.
| Antimicrobial agent (μg) | Number of isolates (%) |
||
|---|---|---|---|
| R/ESBL | I/ESBL | S/ESBL | |
| AMP (10) | 33 (100)/32 (97.0) | - | - |
| FOX (30) | 7 (21.2)/7 (21.2) | 5 (15.2)/5 (15.2) | 21 (63.6)/20 (60.6) |
| CTX (30) | 33 (100.0)/32 (97.0) | - | - |
| CAZ (30) | 32 (100.0)/32 (100.0) | - | 1 (3.03)/0 (0.0) |
| CRO (30) | 33 (100.0)/32 (97.0) | - | - |
| NAL (30) | 10 (30.3)/10 (30.3) | 9 (27.3)/8 (24.2) | 14 (42.4)/14 (42.4) |
| CIP (5) | 10 (30.3)/10 (30.3) | 16 (48.5)/15 (45.4) | 7 (21.2)/7 (21.2) |
S, susceptibility; I, intermediate; R resistant; AMP, ampicillin; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FOX, cefoxitin; NAL, nalidixic acid and CIP, ciprofloxacin.